Choueiri, T. K. & Motzer, R. J. Systemic therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 376, 354–366 (2017).

CAS  Article  Google Scholar 

Motzer, R. J. et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 20, 71–90 (2022).

Article  Google Scholar 

Zambrana, F. et al. Complete response and renal cell carcinoma in the immunotherapy era: the paradox of good news. Cancer Treat. Rev. 99, 102239 (2021).

CAS  Article  Google Scholar 

Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289–1300 (2021).

CAS  Article  Google Scholar 

Bartlett, V. L., Dhruva, S. S., Shah, N. D., Ryan, P. & Ross, J. S. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw. Open 2, e1912869 (2019).

Article  Google Scholar 

Mar, N., Kaakour, D. & Rezazadeh Kalebasty, A. Renal cell carcinoma-lessons in diversity, breakthroughs, and challenges. JCO Oncol. Pract. 18, 197–199 (2022).

Article  Google Scholar 

Ged, Y. & Voss, M. H. Novel emerging biomarkers to immunotherapy in kidney cancer. Ther. Adv. Med. Oncol. 13, 17588359211059367 (2021).

CAS  Article  Google Scholar 

Braun, D. A. et al. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nat. Rev. Clin. Oncol. 18, 199–214 (2021).

CAS  Article  Google Scholar 

Choueiri, T. K. & Kaelin, W. G. Jr. Targeting the HIF2–VEGF axis in renal cell carcinoma. Nat. Med. 26, 1519–1530 (2020).

CAS  Article  Google Scholar 

Choueiri, T. K. et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 27, 802–805 (2021).

CAS  Article  Google Scholar